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Abstract
Federal expenditures are under scrutiny in the United States, and the merits of continuing and
expanding the President’s Emergency Plan for AIDS Relief (PEPFAR) to support access to
antiretroviral therapy have become a topic of debate. A growing body of research on the economic
benefits of treatment with antiretroviral therapy has important implications for these discussions.
For example, research conducted since the inception of PEPFAR shows that HIV-infected adults
who receive antiretroviral therapy often begin or resume productive work, and that children living
in households with infected adults who are on treatment are more likely to attend school than
those in households with untreated adults. These benefits should be considered when weighing the
overall benefits of providing antiretroviral therapy against its costs, particularly in the context of
discussions about the future of PEPFAR. A modest case can also be made in favor of having
private companies in HIV-affected countries provide antiretroviral therapy to their employees and
dependents, thus sharing some of the burden of funding HIV treatment.
Since its inception in 2003, the President’s Emergency Plan for AIDS Relief (PEPFAR) has
enabled resource-constrained countries to treat millions of HIV-infected children and adults
with antiretroviral therapy. The direct clinical benefits of antiretroviral therapy—reduced
patient morbidity and mortality—have been well documented and are the most immediate
and important returns on PEPFAR’s investments. However, these are not the sole benefits.
A small but important body of literature has documented substantial improvements in the
socioeconomic well-being of those who receive antiretroviral therapy and of their household
members.
Amid the recent focus of donors and international agencies on reducing the costs of
antiretroviral therapy1 and on strategies for increasing the cost-effectiveness of treatment
delivery,2 the economic benefits generated by antiretroviral therapy provision have received
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relatively limited attention. Moreover, cost-effectiveness estimates of antiretroviral therapy
have been used to influence resource allocation decisions, even though such estimates rely
on narrow metrics and exclude important social and economic benefits.3
Any examination of the economic consequences of treatment for HIV/AIDS must draw on
the substantial amount of evidence on the effects of HIV/AIDS itself at the individual,
household, and community levels. Prior to the expansion of large-scale treatment in the
developing world, several studies quantified the extent to which labor productivity declined
as HIV infection progressed.4 The studies showed a large reduction in economic activity for
people whose condition had progressed to AIDS.
Moreover, because those most likely to acquire HIV and eventually develop AIDS were
working-age adults, their reduced productivity and eventual death had consequences for the
well-being of other household members. These consequences included the added burden
placed upon household members to compensate for the lost labor of the sick adults. Children
living in a household with an HIV-infected adult also had a greater risk of poorer nutrition
and schooling outcomes. Other studies found that premature adult mortality in Africa, most
of it of due to HIV/AIDS, had a detrimental effect on employer production costs5 and the
efficiency of government services delivery.6
The overall magnitude of these effects varied widely among and within countries, but it was
frequently large. We argue that the potential for antiretroviral therapy programs to reverse
these effects is an important consideration, and that the social and economic benefits of
these programs should be considered when discussing not only the future of PEPFAR but
also global investments in HIV treatment more generally.
In this article we synthesize the findings of key studies of the economic impact of
antiretroviral therapy programs that have been supported by PEPFAR and others. We
believe that these studies indicate that economic returns on investments in antiretroviral
therapy programs are likely to be large and important enough to warrant consideration in
policy debates.
A comprehensive review of these studies is beyond our scope, and in any case, our overall
aim is to identify the general conclusions of the studies and consider their implications. As
we discuss further below, the economic effects of the programs occurred at the levels of the
people receiving antiretroviral therapy, their households, and their employers.
In view of the potential benefits that employers can realize by providing antiretroviral
therapy to employees, we consider the prospects for private-sector support for antiretroviral
therapy programs. We conclude by discussing the implications of these results in light of the
ever-increasing number of adults who face a lifetime of reliance on antiretroviral therapy
and the recent evidence showing the preventive benefits of treatment.
We do not discuss the literature about possible macroeconomic impacts of antiretroviral
therapy programs or HIV/AIDS, but interested readers should consult the paper by Erik
Lamontagne and coauthors7 for a discussion of this topic.
Economic Benefits To Individuals
At the most basic level, antiretroviral therapy leads to a dramatic improvement in the
survival and health of HIV-infected people who have progressed to the latter stages of the
disease. In principle, this improvement in health status and functional capacity should be
accompanied by a greater ability to do productive work. Considerable evidence now shows
that this is indeed the case.
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Two early studies conducted in Kenya focused on populations of patients who were
primarily engaged in subsistence or estate agriculture.8,9 Both studies showed that within
twelve months of initiating antiretroviral therapy, patients were working in excess of 30
percent more (as measured in hours or days worked) than they had before starting
antiretroviral therapy. The increase in employment levels as a result of anti-retroviral
therapy would be even greater if the likelihood of reduced employment levels in the absence
of antiretroviral therapy were used as the relevant comparison.
Studies that observed treated patients over a longer period of time, up to three years after the
initiation of treatment, confirmed that initial employment increases were sustained. In South
Africa, employment rates among treated patients rose from 27 percent to 42 percent in the
three years after the patients began antiretroviral therapy.10 In India, the percentage of
patients who were employed rose from 28 percent to 65 percent in a two-year period.11
Two comprehensive reviews of these and many other studies12,13 suggest that the findings
described above can be generalized to various settings, such as countries with high and low
prevalence of HIV/AIDS and rural and urban areas.
A treatment program alone, however, may not provide all the necessary conditions for HIV-
infected adults to fully restore their livelihoods. The available, albeit limited, evidence
suggests that men see more employment gains after initiating antiretroviral therapy than
women do.11,14 This, in turn, suggests a gender disparity in the economic benefits of
treatment.
Antiretroviral therapy is much less likely to improve health outcomes if patients seek care at
very late stages of HIV.15 Finding ways to detect HIV cases early and retain patients in care
before beginning antiretroviral therapy, and then initiating the therapy as soon as patients are
determined to be medically eligible, is desirable not only for clinical reasons but for a
number of economic reasons, as we discuss below.
Socioeconomic Benefits To Households
Households are interconnected groups of people who jointly allocate their time and
resources to earn income, save, and consume. Because of these interconnections, the
productivity benefits realized by adults initiating antiretroviral therapy can directly benefit
other household members.
Previous studies have identified three benefits that are particularly important to households
in resource-limited settings: averted end-of-life health and funeral expenditures; adjustments
in time allocated by children to schooling and work; and preventing children in the
household from becoming orphans. A common theme in this literature is that these benefits
are particularly relevant for poorer and more labor-constrained households.16
AVERTED END-OF-LIFE EXPENDITURES
Prior to the antiretroviral therapy era, when adults with HIV/AIDS experienced deteriorating
health, their households accessed and paid for substantial amounts of health care
services.17,18 After death, expenses for conducting funerals and social events according to
cultural norms placed a burden on household members, extended families, and local
communities.
Several early studies documented the magnitude of such costs. For lower-income
households in South Africa, funerals were estimated to cost the equivalent of several months
of household income.17 In Tanzania, one study estimated that medical costs incurred by an
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HIV/AIDS patient just prior to death, combined with funeral expenses, were equivalent to
the estimated annual per capita household income for that country.19
These catastrophic expenditures could be major factors in instances of nonpoor households
falling into poverty. The reduction of mortality due to HIV/AIDS made possible by
antiretroviral therapy programs has meant that end-of-life expenditures have been avoided
or, at the very least, delayed by a number of years. Of course, even when there is no user fee
to patients, antiretroviral therapy has associated indirect costs, such as transportation to the
clinic and time lost from work. Even so, these recurrent costs of accessing so-called free
antiretroviral therapy are much less damaging to household finances than the costs of
funerals and treating opportunistic illnesses.
LESS WORK AND MORE SCHOOLING FOR CHILDREN
Antiretroviral therapy may influence the outcomes of children in several important ways.
School attendance and work are two competing uses of time among children. Our theory is
that as adults return to work after initiating antiretroviral therapy, income and health
improvements allow households to make adjustments in children’s education and labor.
Women and especially children do not have to spend as much time in care-giving activities
throughout the day.
Substitution of adult labor for child labor, especially in farming activities, also frees up more
time for children to participate in school. Finally, with increases in income, households have
more resources to pay children’s education expenses, such as the cost of uniforms and
school supplies, as well as school fees, where required.
Although antiretroviral therapy is likely to have the above effects, the empirical evidence
remains limited and ambiguous. Before the reach of antiretroviral therapy was substantially
expanded, HIV/AIDS deaths in a household had little empirical impact on the time use of
other household members, including children, perhaps because labor was not particularly
scarce in study regions.
A clear negative impact on schooling was estimated in some studies20 but was not uniform
across countries.21,22 Nonetheless, antiretroviral therapy for adults has been linked to
improvement in children’s outcomes.
One study from Kenya reported that school attendance, measured as hours attending school
per week, of children living in households with at least one HIV-infected adult increased by
more than 20 percent within six months of that adult’s initiating treatment.23 The timing of
the school attendance improvements, usually within six months after an adult household
member initiated antiretroviral therapy, coincided with large improvements in the
employment outcomes of the treated adults.
Related studies also showed that young boys and girls worked substantially less after adults
in their households began receiving antiretroviral therapy.9,24 Additional studies to examine
what happens within households of antiretroviral therapy recipients would strengthen the
evidence base about the broader economic consequences of treatment programs and enable
more accurate calculations of the economic benefits of investments in antiretroviral therapy.
PREVENTING THE ORPHANING OF CHILDREN
Between 2005 and 2010, PEPFAR spent more than $1.5 billion on programs providing
support to orphans and vulnerable children. PEPFAR will spend an even larger amount on
support for orphans and vulnerable children in 2012.25 Orphans and vulnerable children
typically live in households with a surviving parent, grandparent, and other relatives, as well
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as nonrelatives on occasion. Many of these households are poor, which is often a major
justification for programs designed to help orphans and vulnerable children.
Rigorous impact evaluations of the economic benefits of PEPFAR-supported programs for
orphans and vulnerable children do not exist, but assessments of other effects can be found.
By keeping adults with children alive and productive, antiretroviral therapy keeps children
from becoming orphans. On average, for every two adults who initiate treatment, one child
does not become orphaned.13 A reduction in orphaning also results in less recurrent
psychological trauma, exploitation, and sexual abuse experienced by children.26
Although national AIDS programs and local communities save resources if there are fewer
orphans to support, such cost savings are likely to remain modest unless orphans and
vulnerable children programs change considerably. For example, PEPFAR-supported
programs for orphans and vulnerable children, as actually implemented, have been estimated
to cost $20–40 per person per year in direct program expenses at the local level. Part of the
reason for the relatively low cost is that these programs have taken advantage of large
quantities of free time provided by volunteers in the local community.27,28
Savings on orphans and vulnerable children programming would be substantially larger if
such programs were funded to provide a fuller package of services (see, for example, the
article by Stover and colleagues29 for a description of a full package of services, along with
annual costs).
Economic Benefits To Employers
Formal-sector employment, although low in most low-income countries, also stands to gain
from making antiretroviral therapy accessible. Several countries have models of employer-
sponsored antiretroviral therapy programs that have included on-site treatment and
facilitated access to private or public HIV clinics through targeted subsidies. In addition, a
number of multinational and other large companies operating in sub-Saharan Africa offer
antiretroviral therapy to employees and their dependents. The Heineken International
brewing company is one example.30–32 The presence of such employer-sponsored HIV
programs and their benefits may help spur other employer-based programs.
Some evidence suggests that making antiretroviral therapy accessible to employees may
generate positive financial returns to companies.5,33 Certain types of job-specific experience
and institutional memory may not be easily replaced after the loss of existing employees.
The business argument for making antiretroviral therapy accessible to workers is that by
reducing morbidity and mortality among employees, companies can limit disruptions in their
production processes and avoid costs associated with the hiring and retraining of new
employees.34
A few studies have documented this effect, especially at companies with relatively high-
value output, such as utility companies and diamond companies.35–37 On balance, the
evidence suggests that private companies may have incentives to contribute at least partially
to making antiretroviral therapy accessible to employees, particularly when there is an
option to refer employees to public health facilities that offer free or heavily subsidized
treatment. The benefits to companies can be large enough to motivate some to cover the full
costs of antiretroviral therapy, and companies are more likely to do so as treatment costs
decrease.
Providing private health insurance for employees and their families is another way that
employers can increase access to antiretroviral therapy. Incentive programs have also been
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proposed, such as tax exemptions for companies that make antiretroviral therapy accessible
to employees.
Governments may try to reduce the costs of providing public-sector antiretroviral therapy
programs by incentivizing employer-based programs. These may not effectively address the
fiscal problem for governments, however, because cost savings would be offset by a loss of
tax revenues. Other strategies, such as coordinated drug procurement and price negotiation
could also be explored.
In countries where the formal sector constitutes a larger share of the economy, public-
private partnerships may present a source of cost savings to PEPFAR if government
programs can take advantage of private companies’ resources for providing insurance or
direct treatment to employees. But even in countries where PEPFAR-supported programs
provide antiretroviral therapy to employees, the economic benefits that accrue to companies
should not be overlooked. Although the public sector bears the cost of providing
antiretroviral therapy, the private sector realizes benefits, and these benefits should be
included in cost-benefit calculations along with the impact on individuals and households.
In sum, after nearly a decade of expanded access to antiretroviral therapy in developing
countries, numerous studies have shown that the benefits of the treatment extend beyond
direct health improvements among patients. Increased employment and labor productivity,
better outcomes for the children of patients, and improved household welfare all contribute
to the positive story that unfolds when a population gains access to HIV/AIDS treatment.
Looking Ahead: Implications For PEPFAR’s Next Decade
At a time when the United States is slowly recovering from a severe economic recession,
when federal budget deficits are high, and all budgetary expenditures are under increased
scrutiny, questions may be raised about the value of maintaining PEPFAR as a major US
foreign assistance program. The growing body of research on the economic gains achieved
by antiretroviral therapy programs has several important implications for this debate.
ECONOMIC RETURNS
We have not quantified the dollar value of the benefits stemming from PEPFAR’s support
for antiretroviral therapy. Such an exercise would require accounting for the various
beneficial effects of treatment and falls beyond the scope of this article. Additional empirical
estimates of the effects of antiretroviral therapy would also enable more careful estimation
of the total benefits of the therapy.
However, on balance, findings suggest that the economic benefits of antiretroviral therapy
are an important addition to the fundamental benefits of survival and reduced morbidity. In
fact, there are reasons to believe that the benefits are substantial and might offset the costs of
treatment.
To start with, estimates from studies conducted in just one site in Kenya, with assumptions
about various parameters such as the return to education, can be used to calculate the value
of employment and education gains enabled by antiretroviral therapy.9,23 These calculations
—as well as a recent analysis of the Global Fund for AIDS, Tuberculosis, and Malaria13—
have shown positive returns on investment in antiretroviral therapy programs. Money spent
on financing treatment programs is thus likely to provide substantial economic returns to
individuals, households, and employers in HIV-affected countries.
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TREATMENT AS PREVENTION STRATEGIES
There have been increased calls for earlier initiation of antiretroviral therapy in HIV-
infected people based on the recent HPTN-052 study’s findings that early initiation of
therapy dramatically reduced HIV transmission risk.38 The study showed that among
discordant couples (in which one person is infected with HIV and the other is not), provision
of antiretroviral therapy at an early stage to the HIV-infected person resulted in a 96 percent
reduction in the rate of HIV transmission to the uninfected person. Thus, there is a growing
appreciation of strategies that include more proactive detection of HIV in the community
and earlier initiation of antiretroviral therapy. The existing evidence on the socioeconomic
impact of antiretroviral therapy can provide some guidance for policy decisions in this
realm.
We believe that economic outcomes of HIV-infected individuals typically begin to decline
well before treatment is initiated. If this is true—and, admittedly, the evidence at the
moment is limited to a relatively few economic assessments of people in the early stages of
HIV infection—then earlier initiation of antiretroviral therapy could help prevent household
economic losses and setbacks in children’s schooling. Clearly, more research is needed on
this question. Findings from such research would allow for a more comprehensive
evaluation of HIV prevention approaches like the “test and treat” strategy that calls for
universal HIV testing and immediate antiretroviral therapy initiation.
PUBLIC-PRIVATE PARTNERSHIPS FOR COST REDUCTION
Cost considerations and limitations in resource availability are likely to govern decisions
about treatment program expansion. A modest case could be made in favor of private
companies’ using some of their own resources to provide antiretroviral therapy to employees
and their dependents. The argument would be most persuasive for large companies, which
are more likely than smaller ones to provide some health care benefits already, and for
companies that rely on a skilled labor force, where employees cannot be easily replaced.5
This would enable some cost savings for PEPFAR, but a key limitation would be the small
size of the formal sector in most countries that PEPFAR supports.
LIMITATIONS OF COST-EFFECTIVENESS ANALYSES
The high level of scrutiny applied to the cost of PEPFAR-supported antiretroviral therapy
programs should be matched with a corresponding amount of attention to their
socioeconomic benefits. Such attention would help ensure that future policy and resource
allocation decisions were well balanced.
To date, most research on the economics of antiretroviral therapy has been framed as cost-
effectiveness analysis, aimed at determining how the treatment compares to other public
health programs in terms of the cost per unit of improvement gained in patient survival and
general health.3 Economic gains to patients and their households, employers, and societies at
large are usually not taken into account in cost-effectiveness analyses. However, these gains
should be recognized when weighing the overall benefits of providing antiretroviral therapy
against its overall costs. Crucially, the conclusions that policy makers draw about the
desirability of investments in antiretroviral therapy may differ greatly depending on whether
they are relying on such cost-benefit analyses or cost-effectiveness analyses.
When PEPFAR was launched in 2003 and re-authorized in 2008, its goal was fundamentally
humanitarian. It aimed to save lives and reduce human suffering, and its numerical targets—
millions of new infections prevented, patients placed on treatment, children offered care and
support—reflected the goal of having a large and rapid impact.
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Although criticism can be leveled against some aspects of PEPFAR’s programming, its
success in expanding access to antiretroviral therapy, and consequently in saving millions of
lives, is undeniable. What was not explicitly recognized at the time of PEPFAR’s inception,
however, is that making treatment available to working-age adults is not solely a
compassionate gesture. The benefits of treatment in terms of labor productivity, children’s
welfare, and retention of skills and experience make PEPFAR a key instrument for investing
in economic development.
As debates continue about the level of funding that the United States is willing to commit to
the global fight against HIV/AIDS, the potential for PEPFAR to realize positive returns as a
productive investment in long-term economic development should be given considerably
more weight.
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